All In Biotech

Drug Trial Radar · NCT05645276

A Study of AK129 in Patients With Advanced Malignant Tumors

A Phase Ia/Ib, Open Label, Dose Escalation and Dose Extension Trial of Anti-PD-1 and LAG-3 Bispecific Antibody AK129 to Evaluate the Safety, Tolerability and Antitumor Efficacy in Patients With Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

57

Actual

Start

Mar 3, 2023

Primary completion

Jun 9, 2026

Study completion Jun 9, 2026

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Dec 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase Ia/Ib, open label, dose escalation and dose extension trial of Anti-PD-1 and LAG-3 bispecific antibody, AK129, to evaluate the safety, tolerability and antitumor efficacy in patients with advanced malignant tumors

Conditions

  • Advanced Malignant Tumors(Stage IA-IB)

Interventions

  • AK129 IV infusionDrug

    AK129 is administered intravenously according to the frequency and dosage of administration at different stages.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events(AE)Time frame: Up to approximately 2 years
  2. Incidence of serious adverse events(SAE)Time frame: Up to approximately 2 years
  3. The incidence of suspected unexpected serious adverse reactions(SUSAR)Time frame: Up to approximately 2 years
  4. Incidence of dose-limiting toxicity(DLT)Time frame: Up to approximately 2 years
  5. Number of participants with clinically significant changes in laboratory assessment data as assessed by CTCAE v5.0.Time frame: Up to approximately 2 years
  6. AE that leads to the termination or suspension of treatmentTime frame: Up to approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Science

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.